Overview

Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients

Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
This study involves adding the kinase inhibitor Ruxolitinib to Ibrutinib to treat Chronic Lymphocytic Leukemia (CLL).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborator:
Novartis